Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $231
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn maintains an Overweight rating on AbbVie and raises the price target from $218 to $231.
October 31, 2024 | 12:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has reaffirmed its Overweight rating on AbbVie and increased the price target from $218 to $231, indicating a positive outlook.
The increase in price target from $218 to $231 by Morgan Stanley suggests a positive outlook for AbbVie, likely leading to a short-term increase in stock price. The Overweight rating indicates confidence in AbbVie's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100